Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.
Michael J HallerDesmond A SchatzJay S SkylerJeffrey P KrischerBrian N BundyJessica L MillerMark A AtkinsonDorothy J BeckerDavid BaidalLinda A DiMeglioStephen E GitelmanRobin GolandPeter A GottliebKevan C HeroldJennifer B MarksAntoinette M MoranHenry RodriguezWilliam RussellDarrell M WilsonCarla J Greenbaumnull nullPublished in: Diabetes care (2018)
Low-dose ATG slowed decline of C-peptide and reduced HbA1c in new-onset T1D. Addition of GCSF did not enhance C-peptide preservation afforded by low-dose ATG. Future studies should be considered to determine whether low-dose ATG alone or in combination with other agents may prevent or delay the onset of the disease.